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Abstract
Background: Bacterial transglutaminases are increasingly required as industrial reagents for in vitro modification of
proteins in different fields such as in food processing as well as for enzymatic site-specific covalent conjugation of
therapeutic proteins to polyethylene glycol to get derivatives with improved clinical performances.
In this work we studied the production in Escherichia coli of a recombinant transglutaminase from Streptomyces
mobaraensis (microbial transglutaminase or MTGase) as enzymatically active chimeric forms using different expression
systems under the control of both lac promoter or thermoinducible phage lambda promoter.
Results: Thermoinducible and constitutive expression vectors were constructed expressing Met-MTGase with chimeric
LacZ1-8PNP1–20 or LacZ1–8 fusion protein under different promoters. After transformed in competent Escherichia coli K12
strains were fermented in batch and fed-bach mode in different mediums in order to select the best conditions of
expression.
The two most performing fusion protein systems namely short thermoinducible LacZ1–8Met-MTGase from NP668/1
and long constitutive LacZ1–8PNP1–20Met-MTGase from NP650/1 has been chosen to compare both efficiency of
expression and biochemical qualities of the product. Proteins were extracted, purified to homogeneity and verified as a
single peak obtained in RP-HPLC. The LacZ1–8PNP1–20Met-MTGase fusion protein purified from NP650/1 exhibited an
activity of 15 U/mg compared to 24 U/mg for the shorter fusion protein purified from NP668/1 cell strain.
Conclusions: Combining the experimental data on expression levels and specific activities of purified MTGase fusion
proteins, the chimeric LacZ1–8Met-MTGase, which displays an enzymatic activity comparable to the wild-type enzyme,
was selected as a candidate for producing microbial transglutaminase for industrial applications.
Background
Transglutaminases (TGases, protein-glutamine γ − gluta-
myltransferase, E.C.2.3.2.13) are a large family of multi-
functional enzymes occurring in several organisms,
including mammals, invertebrates, plants and micro-
organisms. These enzymes catalyze an acyl transfer
reaction between the γ-carboxyamide group of a peptide-
bound glutaminyl residue (acting as acyl donor) and a
variety of primary amines (acting as acceptor) including
the ε-amino group of a peptide-bound lysine, resulting in
the formation of a new γ-glutaminyl covalent link and
ammonia [1].
It is widely demonstrated that transglutaminase is
involved in several physiological process. For instance, it
serves a key factor in pancreatic fl-cell during glucose-
stimulated insulin release through Ca2+ dependent
enzyme reaction in isolated islets of Langerhans [2].
Moreover, transglutaminase family is widely expressed
in cardiovascular cells and in macrophages, and the recent
studies have documented diverse roles for transglutami-
nases in cardiovascular pathophysiology, in chronic as well
as the acute manifestations of atherosclerosis (e.g., plaque
rupture). Transglutaminases can modulate several cardio-
vascular risk factors, especially hypertension [3].
The ability to promote covalent modifications of pro-
teins by intra- and intermolecular linkages catalyzed by
tranglutaminases is also exploited in industrial food as
an established procedure to improve the texture and the
nutritional value of different foods [4]. More recently,
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based on mild operative conditions and the recognition
of specific substrate sequences, transglutaminases have
been proposed as efficient catalysts for site-specific label-
ing of proteins with ligand molecules, as for example in
the case of enzymatic pegylation of recombinant thera-
peutic proteins whose pharmacokinetics and/or pharma-
codynamic properties can be modulated by covalent
binding of high molecular weight poly(ethylene glycol)
moieties [5].
Known microbial transglutaminases (MTGase) differ
from the mammalian enzymes in that they lack any
sequence homology, display Ca2+ independent activity and
have smaller molecular masses [6]. Due to their proper-
ties, including Ca2+ independent activity, high reaction
and broad specificity for acyl donors, microbial transgluta-
minases are advantageously used in industrial application
both in food and in pharmaceutical fields.
A microbial transglutaminase (MTGase) from Strep-
toverticillium mobaraensis (S.mobarensis) has been
isolated, characterized and cloned [7]. This protein,
which consists of 331 amino acids with a molecular
mass of 37.9 kDa, is biosynthesized as a pre-pro-
protein, then secreted from cytoplasmic compartment
as inactive pro-MTGase which is finally activated by
proteolytic processing to the enzymatically active ma-
ture form [8].
MTGase was first prepared by conventional cultivation
of wild-type strain of S.mobaraensis where the secreted in-
active pro-enzyme was activated by endogenous proteases
[9]. Later on, a number of reports have described the pro-
duction of MTGase in different recombinant bacterial
hosts such as Streptomyces lividans [10, 11], Lactococcus
lactis [12] and Escherichia coli [13]. Because of its protein
cross linking activity, MTGase is a potentially toxic agent
for the recombinant expression hosts if produced intracel-
lularly in an active form. Therefore, the expression as
functionally inactive pro-enzyme with subsequent in vitro
activation by cleavage of the pro-sequence or, alternatively,
the expression of mature MTGase as insoluble inclusion
bodies followed by in vitro refolding is necessary.
In a previous work, we found that recombinant proteins
bearing an N-terminal extension consisting of a few LacZ
residues followed by the first twenty residues of the
enzyme purine nucleoside phosphorylase (PNP1–20) when
expressed in Escherichia.coli (E.coli), were invariably accu-
mulated at high level inside the cell as cytoplasmic
inclusion bodies [14]. In the present paper we describe the
application of the same fusion protein technology for
producing recombinant MTGase in E.coli according to
different expression systems comprising a constitutive and
thermoinducibile one under the control of the λ phage
promoter. The results confirmed the critical importance
of the N-terminal extension to obtain both high level
expression of MTGase and its cytoplasmic segregation in
inclusion bodies. Starting from washed inclusion bodies
we also developed an efficient refolding and purification
protocol to obtain a final MTGase preparation which
displayed highly specific activity.
In conclusion, the procedure described in this work
could potentially be applied for producing pure recom-
binant MTGase on a commercial scale for subsequent
use as a convenient biocatalyst for the preparation of
new protein conjugates.
To date, the mainly bacterial expression system to bio-
synthesise transglutaminases is (S.mobarensis), this system
however has some drawbacks, involving, e.g. problems
related to post-translational protein modification [4]. In
this work we present a cheaper and more efficient system
based on the E.coli peculiarity to highly express recombin-
ant proteins by inclusion body identifying and developing
the most performing expression system, the procedure
described could therefore potentially be applied for produ-
cing pure recombinant MTGase on a commercial scale
for subsequent use as a convenient biocatalyst for the
preparation of new protein conjugates.
Methods
General methods
All DNA manipulations, including restriction digestions,
ligations and electrophoresis on agarose gels, were carried
out as described [15]. Restriction and DNA-modifying en-
zymes were purchased from New England Biolabs (Beverly,
MA, USA) and used according to the manufacturer’s
instructions. PCR experiments were performed using a
PCR thermal cycler (Gene Amp® PCR System 2700,
Applied Biosystems), a high fidelity PCR system (PfuTurbo
Hot Start and Easy A Hi Fi from Stratagene) and oligonu-
cleotides synthesized by M-Medical (Milan, Italy). Plasmid
extractions from agarose gels and PCR purifications were
performed using Qiagen kits. The competent cells were
transformed using the Bio-Rad E. coli Pulser transformation
apparatus and selected using antibiotic resistance.
Soytone, yeast extract and all other chemicals and
components for the preparation of culture media were
from Merck, Sigma-Aldrich or Fluka.
Synthetic cDNA coding for Met-MTGase
cDNA coding for mature S.mobaraensis MTGase (Gen-
Bank database accession n° DQ132977) optimized accord-
ing to E.coli codon usage was synthesized by Sloning Bio
Technology GmbH (Puchheim, Germany) using a propri-
etary genetic algorithm. Essentially, rare codons were
replaced with the most frequently used E.coli codon for
each particular amino acid. Other parameters such as GC-
content bias, stability of the RNA secondary structure and
length of direct and inverted repeats were also assessed
following codon optimisation.
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A starting ATG codon for Met residue at the N-terminus
and two consecutive stop codons TAA TGA at C-terminus
have been added. The synthetic gene was transferred to the
HpaI-XhoI sites of plasmid pPCRScript (from Sloning,
Puchheim, Germany) to give the vector PL444 enconding
for Met-MTGase.
Construction of thermoinducible vectors
The thermoinducible expression vectors were constructed
starting from plasmid PL420 previously prepared in our
laboratory for expressing interferon beta (IFN-β-1b) as
chimeric LacZ1–8PNP1–20 fusion protein under the λ
phage promoter, and characterized for the presence of the
following main components:
– a 1375 bp fragment comprising the PR and PL
promoters and the sequence coding for the
thermosensitive repressor cI857 isolated from
plasmid pND201 [16]
– a coding sequence for IFN-β-1b immediately
dowstream of a oligonucleotide sequence coding for
the first 8 residues of LacZ protein (UniProt/SwissProt
Accession No. Q37953) and the first 20 aminoacids of
E.coli purine nucleoside phosphorylase [14]
– the kanamycine resistance gene and the pUC19
origin of replication
– a multicloning site.
In vectors containing PR and PL promoters of bacterio-
phage λ, transcription may be controlled by the λ repressor,
supplied by expression of cI gene. If a temperature-sensitive
allele of cI is used (e.g., cI857), transcription from the strong
promoters is repressed in cells growing at 30 °C. At 42 °C,
the thermolabile repressor is inactivated and transcrip-
tion is enabled [16]. In our experiments we noticed that
the strong promoter is repressed until 37 °C, therefore
we used this temperature for cell growing and 42 °C for
expression of protein.
The sequence coding for Met-MTGase1–332 was
excised by HpaI-XhoI digestion of PL444 and cloned in
the same restriction sites of PL420 to obtain the vector
PL447 for the expression of mature Met-MTGase
enzyme under the λ phage promoter (Fig. 1, panel a).
The sequence coding for Met-MTGase1–332 was
PCR amplified from PL455 using the sense primer 5′
GTTTAAACGTATGGACAGCGATGACCG 3′ (with
the PmeI site and the Met-MTGase start codon under-
lined) and the antisense primer 5′CTCGAGTCATTAT
GGCCAGCCTTGTTTAAC 3′ (with the XhoI site and
the complementary sequence of a double stop codon
underlined).
The amplified fragment was cloned in pCRII TOPO
(TA Cloning kit, Cat n° K2020-20, Invitrogen) obtaining
PL457 and later restricted by HpaI-XhoI and cloned in the
same restriction sites of PL420 dowstream of sequence
coding for LacZ1–8PNP1–20 to obtain the vector PL464 for
the expression of the chimeric protein LacZ1–8PNP1–20-
Met-MTGase under the λ phage promoter (Fig. 1,
panel b).
The vector for expressing LacZ1–8-Met-MTGase was
constructed using an intermediate vector. The plas-
mid, called PL471, was prepared by PCR amplification
of PL464 with two oligonucleotides that only excluded
the sequence coding for PNP1–20 using the sense pri-
mer 5′ATGGACAGCGATGACCGCGTG 3′ (where
the Met-MTGase start codon is underlined) and the
antisense primer
5′GGAAGAATTCGTAATCATGGTCATAGGTTAAC
3′ (where the first underlined codon is the complemen-
tary codon for the last aminoacid of LacZ1–8 fragment).
Since plasmid PL471 had been amplified by PCR, the re-
gion between the HpaI-XhoI restriction sites of PL471
was sequenced and then transferred into PL464 to ob-
tain the final vector for expressing LacZ1–8Met-MTGase
under the λ phage promoter denominated PL473 (Fig. 1,
panel c).
Construction of constitutive vectors
The constitutive expression vectors were constructed start-
ing from plasmid PL340 previously prepared in our labora-
tory for expressing Met-G-CSF as hybrid LacZ1–8PNP1–20
fusion protein under the lac promoter, and characterized
for the presence of the following main components:
– the lac promoter of commercially available pUC18
vector (ATCC N° 37253)
– a coding sequence for Met-G-CSF immediately
dowstream of a oligonucleotide sequence coding for
the first 8 residues of LacZ protein (UniProt/SwissProt
Accession No. Q37953) and the first 20 aminoacids of
E.coli purine nucleoside phosphorylase [14]
– the tetracycline resistance gene and the pUC18
origin of replication
– a multicloning site.
pUC18 derived vectors containing the inducible lac pro-
moter when transformed into JM109 E.coli strains consti-
tutively express the encoded genes without any addition
of inducing agents such as IPTG or lactose [14, 17].
The sequence coding for Met-MTGase1–332 was amp-
lified by PCR from PL444 using the sense primer 5′
GTTTAAACGTATGGACAGCGATGACCG 3′ (with
the PmeI site and the Met-MTGase start codon under-
lined) and the antisense primer 5′TCTAGAGTCATT
ATGGCCAGCCTTGTTTAAC 3′ (with the XbaI site
and the complementary sequence of a double stop
codon underlined).
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Fig. 1 Construction and structure of MTG expression plasmids. Thermoinducible plasmids, panel: a, b and c (PL447, PL464 and PL473) and constitutive
plasmids, panel: d, e and f (PL458, PL480 and PL472). The restriction enzyme sites used for construction of the plasmids are indicated.
Additional details are described in Methods
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The amplified fragment was cloned in pCRII TOPO
(TA Cloning kit, Cat n° K2020-20, Invitrogen) obtaining
PL456 and later restricted by PmeI-XbaI and cloned in
the same restriction sites of PL340 downstream of se-
quence coding for LacZ1−8PNP1–20 to obtain the vector
PL458 for the constitutive expression of the chimeric
protein LacZ1–8PNP1–20Met-MTGase (Fig. 1, panel d).
The vector for expressing LacZ1–8Met-MTGase under
the lac promoter was constructed using an intermediate
vector called PL463.
The vector was prepared by PCR amplification of PL458
with two oligonucleotides that only excluded the sequence
coding for PNP1–20 using the sense primer 5′ ATGGAC
AGCGATGACCGCGTG 3′ (with Met-MTGase start
codon underlined) and the antisense primer 5′ GGAAG
AATTCGTAATCATGGTCATAGCTG 3′ (where the first
underlined codon is the complementary codon for the last
aminoacid of LacZ1–8 fragment). Since plasmid PL463
had been amplificated by PCR, the region between the
XbaI-SapI restriction sites was sequenced and then
transferred into PL458 restricted with the same en-
zymes to obtain the vector for the constitutive expres-
sion of chimeric LacZ1–8Met-MTGase denominated
PL480 (Fig. 1, panel e).
In order to obtain a plasmid with lac promoter that
expresses Met-MTGase was used a plasmid called
PL469 previously prepared in our laboratory. PL469
contains the tetracycline resistance gene, the pUC18
origin of replication and the LacZ1–8 between NcoI-
XbaI sites. So PL480 was restricted with NcoI-XbaI
and the fragment was inserted into PL469 restricted
with the same enzymes to obtain the vector for the
constitutive expression of Met-MTGase denominated
PL472 (Fig. 1, panel f ).
Cloning and expression of different Met-MTGase and
chimeric Met-MTGase coding vectors
Competent Escherichia coli K12, JM109 cell strains were
transformed by electroporation with several purified plas-
mids as described in Table 1.
Transformed cells were streaked onto agar plates pre-
pared in LS10 medium 5 g/l yeast extract, 10 g/l soytone,
10 g/l sodium chloride containing 12.5 mg/l tetracycline
and incubated in a static incubator (B 12, Heraeus
Instruments) overnight at 37 °C. Four isolated colonies
of each transformed strain were selected from the agar
plates and used to inoculate 10 ml LS10 culture medium
in a 100 ml shake flasks, which were incubated at
220 rpm and 37C overnight in an orbital shaker (Innova
4330, New Brunswick). About 6 ml of each of the incu-
bated cell suspensions were adjusted to a final concentra-
tion of 16 % v/v glycerol, distributed in four cryo-vials and
stored frozen at −80 °C.
About 100 μl were taken from each of four cryo-vials of
the six recombinant strains and used to inoculate 10 ml of
a rich, complex culture medium (18 g/l yeast extract, 10 g/l
soy peptone, 10 g/l glycerol, 3.2 g/l K2HPO4, 0.6 g/l
KH2PO4, 1 g/l MgSO4.7H2O and 0.03 g/l kanamycin) in
100 ml shake flasks incubated overnight using an orbital
shaker at 220 rpm and 37 °C.
1.5 ml samples of each overnight cultures of constitu-
tively expressed recombinant Met-MTGase (NP667,
NP650 and NP676 strains) were pelleted by centrifugation
at +4 °C, washed with 1.6 ml of 20 mM Tris–HCl—1 mM
EDTA—pH 7 buffer, suspended in phosphate buffer saline
to OD600nm value of about 100 and analysed by reducing
SDS-PAGE with Coomassie blue staining.
Overnight cultures of recombinant Met-MTGase
expressed under the λ phage promoter (NP637, NP656
Table 1 List of plasmids and related strains, engineered for different MTGase expression forms in Escherichia coli, fermented in shake
flask for protein expression detection
Plasmid Type Cell strain Promoter Cloned gene Antibiotic resistance
PL444 (Sloning) Starting NP647 Lac promoter Met-MTGase1–332 Amp
PL447 Expression NP637 λ-phage Met-MTGase1–322 Kan
PL456 Intermediate NP648 T7-SP6 Promoter Met-MTGase1–332 Amp-Kan
PL457 Intermediate NP649 T7-SP6 Promoter Met-MTGase1–332 Amp-Kan
PL458 Expression NP650 Lac promoter LacZ1–8PNP1–20 Met-MTGase1–332 Tet
PL463 Intermediate NP655 Lac promoter LacZ1–8Met−MTGase1–332 Tet
PL464 Expression NP656 Phage λ LacZ1–8PNP1–20Met-MTGase1–332 Kan
PL469 Expression NP663 Lac promoter LacZ1–8 Tet
PL471 Intermediate NP666 Phage λ LacZ1–8Met-MTGase1–332 Kan
PL472 Expression NP667 Lac promoter Met-MTGase1–332 Tet
PL473 Expression NP668 Phage λ LacZ1–8Met-MTGase1–332 Kan
PL480 Expression NP676 Lac promoter LacZ1–8Met-MTGase1–332 Tet
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and NP668) were diluted with 50 ml of rich medium
and incubated in 250 ml shake flasks at 37 °C for about
2 h up to an OD600 value of 0.5 ± 0.1. Afterwards the cul-
tures were then incubated for a further 4 h in orbital
shakers at 42 °C.
1.5 ml taken from of each cell suspensions were pre-
pared and analysed by reducing SDS-PAGE as described.
Since no significant difference in terms of cell growth
and recombinant protein expression was observed among
the four clones examined, one from each recombinant
strain was selected at random for Molecular Biology cell
banks to be used for large scale fermentations.
Large scale preparation of MTGase fusion proteins
The production of the MTGase fusion proteins has been
performed using 10-litre scale stirred tank bioreactors
(Biostat C, B. Braun). The compositions of the culture
media employed were originally tested and verified for the
production of other recombinant fusion proteins manu-
factured using the same cell host. Starting from a vial of
the respective Molecular Biology cell banks, the process
consisted of inoculum preparation in shake flask followed
by a 10-litre scale batch or fed-batch production step.
Pre-inoculum was made starting from one vial of the
Molecular Biology cell bank in culture medium FMYb,
an animal free derived media composed by a pre defined
solution of yeast extract, glycerol, vitamins and minerals
with apposite antibiotic and then inoculated in 10 litres
of FMYb culture medium for batch fermentation.
Furthermore, FM1 medium, a solution of yeast extract,
glycerol, soy peptone, minerals and vitamins, was used in
the same conditions for feed-batch and batch fermentation
in order to investigate the best condition of expression.
Bach and Fed-batch process conditions
One vial of the Molecular Biology cell bank was inocu-
lated in 500 ml/flask of FMY and FM1 medium and
cultivated 37 °C at 220 rpm in an orbital shaker (Innova
4300, New Brunswick). Afterwards 100 ml of pre-inocu-
lum was inoculated in 10 litres culture medium: (1 % v/v)
for FMY or (5 % v/v) for FM1.
Cultivation followed for 5 h at 37 °C with air flow
1 v/v/min, pH was controlled to 7.0 ± 0.1 using 12.5 %
v/v NH4OH and 20 % v/v H3PO4. The pO2 saturation
was 20 % controlled by stirring rate at range of 300–
1300 rpm for FMY medium and 300–1500 rpm for
FM1, with a mix of pure oxygen:air at 3:20 supplied
upon reaching highest stirring rate. Minimum stirring
speed was settled at 300 rpm for both media, direct air
sparging was provided using ring sparger with holes on
upper side, agitation using 3 separate flat-bladed (6 blades)
Ruston impellers. Finally, foaming was controlled by anti-
foam addition (Antifoam 204, mixture of organic poly-
ether dispersions).
On-line data acquisition included pH, stirring rate, pO2,
temperature and air flow rate, off-line analyses included
measuring the OD600 and the pH during fermentation.
For fed-batch condition 8 litres of sterile culture media
FM1 was prepared in bioreactor (Biostat C). In corres-
pondence with sharp pO2 increase, indicating slower
growth rate, the feed profile was 2 litres exponential
feeding, 8-hour duplication time, 5 replications with air
flow 1 v/v/min. Foaming and pO2 was controlled as
reported for batch fermentation.
Purification methods
Upon completing fermentation, the cell broths were
harvested and centrifuged (equivalent: 9.000 RCF;
15 min; +4 °C) to obtain concentrated cell paste, which
was then stored frozen at −20 °C until required.
The LacZ1–8Met-MTGase fusion proteins, expressed in
the form of cytoplasmic inclusion bodies, were recovered
by suspending the cell paste (10 % w/v) in 50 mM sodium
phosphate buffer, pH 7.4 containing 100 m M NaCl,
5 mM EDTA and 0.1 % v/v Triton X100 at 4 °C and pass-
ing, for three successive cycles, through a high-pressure
homogenizer (Manton-Gaulin) operated at 650 ± 25 bar.
The cell homogenate (about 6 l) was then cooled to
below +10 °C and batch centrifuged (equivalent: 9.000 RCF;
15 min; +4 °C) to pellet the inclusion bodies. The inclusion
bodies were then washed twice by suspension at +4 °C in
4 l of 50 mM sodium phosphate buffer, pH 7.4 containing
100 m M NaCl, 5 mM EDTA, under agitation for 30–60
min and then collected by centrifugation.
Washed inclusion bodies were finally suspended 1:1 in
50 mM Tris–HCl, 5 mM EDTA, pH 8.0 to form an
homogeneous slurry in a volume of about 3–4 % of ini-
tial cell broth volume, suitably aliquoted and stored fro-
zen at −20 °C until required.
LacZ1–8Met-MTGase inclusion bodies were dissolved
(10 % w/v) in the solubilisation buffer (8 M urea con-
taining 50 mM sodium acetate and 20 mM dithiothreitol
(DTT), pH 5.2) and incubated, in mild agitation, for 1 h
at room temperature. The solubilisation buffer was
added to the washed inclusion bodies preparation at a
constant flow rate within about 10 ml/min, to obtain a
protein concentration of about 3 mg/ml.
The solubilised LacZ1–8Met-MTGase solution was
then diluted 20-fold to a concentration of 0.32 M Urea
using 20 mM sodium acetate, pH 5.2. After 1 h of incu-
bation in mild agitation at +4 °C, the pH was shifted
from 5.2 to 6.0 by adding 1 M NaOH.
The refolded LacZ1–8Met-MTGase protein solutions
were clarified by centrifugation at 17.700 RCF for 10 min
and at 4° to remove any precipitated material and concen-
trated using a 10 kDa cut-off ultrafiltration membrane
(PrepScale-1 ft2, Millipore). The solubilization and refold
reagents used were then removed by dialysis against
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50 mM Tris acetate, pH 8.00 and the protein concentrate
was drained down so that the equipment rinsed with the
dialysis buffer recover residual product.
LacZ1–8Met-MTGase was purified by hydrophobic
interaction chromatography on Phenyl Sepharose 6 Fast
Flow (high substitution) (Fig. 2). The resin was packed
to a column height of 22 cm, column diameter of
16 mm and the column operated at linear flow rates up
to 300 cm/h. The column was equilibrated with 3.5 M
sodium chloride, 50 mM sodium acetate at pH = 5.5
(acetic acid). The load material consisted of the dialysed
sample adjusted to 3.5 M NaCl, acidified to pH 5.5 using
acetic acid diluted 1:20 and filtered 0.22 μm. After load-
ing, the column was washed (4 CV) using the equilibra-
tion buffer. LacZ1–8Met-MTGase was eluted using a
step elution with 0.5 M sodium chloride 50 mM sodium
acetate, pH 5.5. A buffer exchange column was neces-
sary to put the material in the right conditions for the
enzyme-catalysed reaction of pegylation.
Analytical methods
Expression of MTGase and MTGase fusion proteins was
monitored by staining with Coomassie Blue R-250 after
12 % SDS-PAGE analysis [18] of solubilized cells using a
Bio-Rad mini-gel apparatus as well as by RP-HPLC carried
out on a C4 Vydac 214TP52 column (2.1 × 250 mm, 5 μm
particle size, Grace) at 40 °C with UV detection at 215 nm.
MTGase was eluted at 0.2 mL/min starting from the mo-
bile phases A (0.1 % v/v TFA in H2O) and B (0.08 % v/v
TFA in CH3CN) with the following linear gradients: from
30 % to 59 % of phase B in 13 min and from 59 % to 85 %
of phase B in 7 min.
Transglutaminase activity was measured by a described
colorimetric method based on hydroxamate formation
[19]. Briefly, 0.2 mL of 200 mM Tris-buffer pH 6.0 con-
taining 36 mM carbobenzoxy-glutaminyl-glycine, 100 mM
hydroxylamine and 10 mM reduced glutathione were in-
cubated for 10 min at 37 °C with 30 μL of test sample.
The enzymatic reaction was stopped by adding 0.5 mL of
12 % trichloroacetic acid. After that, 0.5 mL of 5 % ferric
chloride exahydrate solutions were added and the result-
ing red color was measured at 525 nm. A calibration curve
was prepared using commercially available L-glutamic
acid γ-monohydroxamate. One unit of MTGase activity is
defined as the amount of enzyme that catalyzes the for-
mation of 1.0 μmole of hydroxamate/min at the above
Fig. 2 Hydrophobic interaction chromatography of LacZ1–8Met-MTGase on phenyl Sepharose with a step elution of 0,5 M sodium chloride, 50 mM
sodium acetate, pH 5.5 buffer, at room temperature
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reported conditions. Specific activity is expressed as
MTGase units/mg of protein.
Purity and concentration of MTGase were determined by
HPLC analysis. SE-HPLC was carried out using a TSKgel
SuperSW3000column (4.6 × 300 mm, 4 μm particle size,
Tosoh Bioscience). The column was thermostated at 25 °C
and eluted with 0.05 M NaH2PO4, 0.4 M NaClO4, pH 6.0,
at a flow rate of 0.35 mL/min. The UV detector was set at
215 nm. RP-HPLC was performed on a C4 Vydac 214TP54
column (4.6 × 250 mm, 5 μm particle size, Grace),
thermostated at 55 °C and equilibrated with 75 % (v/v)
buffer A (0.1 % TFA v/v in H2O) and 25 % (v/v) buffer B
(0.08 % TFA v/v in CH3CN). The enzyme was eluted at a
flow rate of 0.8 mL/min with a linear gradient from 25 % to
45 % of buffer B in 23 min, recording the absorbance at
215 nm. Quantization was carried out by the external
standard method, using a standard bovine serum albumin
(BSA) solution as reference solution.
We also verified the functionality of the obtained
recombinant transglutaminase by the process for site-
specific pegylation of Met-GCSF developed by Bio-Ker
[20]. Briefly Met-GCSF was submitted to covalent conju-
gation at glutamine 135 residue with a 20 kDa amine
derivative of polyethylene glycol (PEG20kDa-NH2) via
enzyme-catalysed reaction using the purified Ajinomoto
“wild type” microbial transglutaminase in comparison
with the purified LacZ1–8Met-MTGase from NP668/1.
The experimental conditions where PEG/Met-GCSF ra-
tio 10:1, [Met-GCSF]final 2 mg/ml, [TGase]final 0.25 U/ml
solution, 4 °C, buffer KH2PO4 20 mM and pH 8,1.
Results and discussion
Purity of LacZ1–8Met-MTGase has been evaluated by
electrophoresis and HPLC analysis. A single protein band
was observed on SDS-PAGE gels under both reducing
and non reducing conditions at the expected molecular
weight (Fig. 3). The size-exclusion and reverse-phase
chromatograms showed a single symmetric peak corre-
sponding to 99.6 % and 88.8 % protein purity, respectively,
under native conditions (Fig. 4). The enzyme purity was
confirmed by TGase activity assay which gave a specific
activity of 24U/mg.
Expression systems and assessment
Four different recombinant cell strains, expressing a
Met-MTGase fusion protein with two different N-terminal
fusion partners in two separate expression systems, have
been assessed. Specifically, the long LacZ1–8PNP20Met-
MTGase fusion protein was expressed in cell strains
NP650/1 under constitutive lac promoter and NP656/1
under the thermoinducible phage lambda promoter.
The shorter fusion protein LacZ1–8Met-MTGase, having
just the first eight N-terminal amino acids of beta galacto-
sidase at the N-terminal, was expressed in thermoinducible
cell strain NP668/1 and constitutive cell strain NP676/1
(later replaced by NP676/2). None appreciable level of
protein expression could be discerned by SDS-PAGE
analysis for the strains expressing Met-MTGase without
an N-terminal fusion partner (NP637/1 and NP667/1). All
the others strains possessing an N-terminal fusion partner
yielded a good level of protein expression. Apart from the
NP676 cell strain, expressing LacZ1–8Met-MTGase, which
was characterised by a long time of growth, the other
three cell strains were incubated without problems sug-
gesting that expression of Met-MTGase protein was not
deleterious for the cell host.
Fermentation studies
As a result of preliminary experiments, a total of four
different cell strains were selected to be tested using
the 10-litre fermentation process, namely NP650/1,
NP656/1, NP668/1 and NP676/1 (Table 2). As de-
scribed below the NP676 cell strain was transformed
twice (NP676/2) and also fermented.
The constitutive NP650/1 cell strain yielded a very high
volumetric productivity in terms of cell broth volume of
more than 6 g/l LacZ1–8PNP1–20Met-MTGase fusion pro-
tein for a fed-batch fermentation process. Since this fed
batch process typically lasted from 30 to 45 h, depending
upon the adopted feeding profile, the same cell strain was
tested using a batch process shortening the production
time to about 8 h. However, despite a comparable final bio-
mass content, a relatively low volumetric productivity of
only 1.65 g/l was obtained. These results were confirmed
Fig. 3 SDS-PAGE electrophoresis of reduced and non reduced MTGase
samples stained by Coomassie Blue R-250. Lane 1, protein markers; lane
2, MTGase in non reducing sample buffer; lane 3, MTGase in reducing
sample buffer
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by repeating the processes. In any case, cytoplasmic
expression of the LacZ1–8PNP1–20Met-MTGase fusion
protein didn’t appear to have any appreciable toxic effect
or to be detrimental to the growth of the host cell strain.
The same constitutive expression system was tested
for Met-MTGase having the shorter N-terminal fusion
partner (cell strain NP676/1) but all of four fed-batch
production runs were terminated due to excessive
foaming.
Considering that in other similar experiments, constitu-
tive systems expressing long LacZ1–8PNP1–20Met-MTGase
fusion protein had no apparent toxic effect on the cells, we
repeated the previous experiment transforming again the
plasmid in a newly aliquot of competent cells obtaining a
new cell bank named NP676/2. The new transformed cell
strain was also characterized by slow growth, anyway two
fed-batch fermentation processes have been completed,
resulting in a final volumetric productivity of about 2.5 g/l
and a specific productivity, product titre in terms of grams
cell wet weight, of about 36 mg/g.
Five fermentation batches using the thermo-inducible
NP656/1 cell strain expressing the LacZ1–8PNP20Met-
MTGase fusion protein were performed, the fermenter
temperature was shifted to 42 °C at an OD600 value of 13
after 3.5 h incubation and a final product yield of 3 g/l
was obtained. In another batch the temperature shift
was performed after 5.5 h incubation, at an OD600 value
of 36, resulting in a lower final volumetric productivity
of 1.65 g/l.
In both batches, an high level of protein expression
has been obtained after only four hours post-induction
and no expressed product were observed before induc-
tion. In a third batch, the temperature shift was per-
formed after 2 h incubation at a very low OD600 value of
4.5 which resulted in a low final biomass content (final
OD600 value of 18) and a lower product yield of 1.3 g/l.
The highest volumetric productivity, 3.85 g/l, was ob-
tained when the temperature shift was performed at an
OD600 value of 18, corresponding to the mid-point of
the exponential growth phase.
In addition to the above described fermentations op-
erated in a batch mode, similar five batches were run
in a fed-batch mode. As result, final biomass and con-
centrations were comparable, but high expression
yield of up to 4 g/l were obtained. Considering only
the fed-batch processes performed using the optimal
conditions, a mean specific productivity value of about
80 mg/g was obtained for NP650/1 compared to about
100 mg/g for NP656/1.
The thermoinducible NP668/1 cell strain expressing
the shorter LacZ1–8MTGase fusion protein yielded a
maximum volumetric productivity of about 3 g/l.
Fig. 4 Reverse-phase (a) and size-exclusion HPLC (b) analysis of purified MTGase from NP668
Table 2 Fermentation of four most performing strains expressing MTGase, comparison of two expression systems
Fusion protein Batch # System FB/batch Final OD600 MTGase (g/batch) Wet mass (g)
LacZ1–8 Met-MTGase NP676/C002 Constitutive Batch 60 26,7 693
NP676/C001 Fed-batch 57 24,1 709
NP668/009 Inducible Batch 54 25,0 540
LacZ1–8PNP1–8 Met-MTGase NP650/C005 Constitutive Batch 58 16,5 790
NP650/C006 Fed-batch 74 62,0 748
NP656/C009 Inducible Batch 46 39,2 335
NP656/C010 Fed-batch 56 42,7 490
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This cell strain was tested according to the batch pro-
duction mode only and, the optimal point for the
temperature shift to 42 °C corresponded to an OD600
value of about 20 (Table 3) giving a mean specific prod-
uctivity of 40 mg/g cell wet weight, while in the same
conditions were obtained for NP656/1 a productivity of
100 mg/g. Shifting the temperature at an OD600 value of
30 or more resulted in a markedly lower yield of 1.2–
2.2 g/l, whereas a value of 2.1 g/l was obtained at a low
OD600 value of 13.
The constitutive NP650/1 cell strain gave the highest
volumetric productivity of 6.15 g/l, on the other hand,
the thermoinducible cell strain NP656/1 exhibited a
lower protein yield, but showed a more specific product-
ivity in terms of mg of protein/cells (wet weight).
For both systems was evident that long LacZ1–8PNP1–
20Met-MTGase fusion protein yielded both a higher
volumetric and specific productivity, demonstrating the
advantage of co-expressing the MTGase protein with the
PNP1–20 peptide. It should be pointed out that this bene-
fit is somewhat reduced if the additional mass, corre-
sponding to about 10 % of the expressed protein, of the
PNP1–20 peptide itself is taken into account.
Purification and quality assessment
According to the preliminary fermentation process studies,
the two most performing fusion protein systems namely
short thermoinducible LacZ1–8Met-MTGase (NP668/1)
and long constitutive LacZ1–8PNP1–20Met-MTGase (NP6
50/1) has been chosen to compare both efficiency of
expression and biochemical qualities of the product.
Proteins were extracted and purified to homogeneity
and so verified as a single peak obtained in RP-HPLC.
The LacZ1–8PNP1–20Met-MTGase fusion protein purified
from NP650/1 exhibited an activity of 15 U/mg compared
to 24U/mg for the shorter fusion protein purified from
Table 3 List of NP668/1 fermentation batches to investigate the
optimal point of temperature shift
Batch # OD600 LacZ1–8Met-
MTGase (mg/l)
Wet mass (g) LacZ1–8Met-
MTGase (mg/g)
NP668/C001 58 1117 744 15,0
NP668/C002 64 2191 604 36,3
NP668/C003 56 3085 493 62,6
NP668/C004 51 1548 646 24,0
NP668/C005 58 2907 590 49,3
NP668/C006 60 2376 580 41,0
NP668/C007 58 2761 560 49,3
NP668/C008 42 2109 384 54,9
NP668/C009 54 2500 540 46,3
NP668/C010 53 2520 538 46,7
NP668/C013 60 2633 591 44,6
NP668/C014 59 2196 564 38,9
NP668/C015 60 1939 572 33,9
NP668/C016 50 2157 575 37,5
NP668/C017 37 1377 522 26,4
NP668/C018 33 2415 497 48,6
NP668/C019 32 1677 571 29,4
Mean 52 2206 563 40,3
Sd 10 541 74 12,0
0,0
20,0
40,0
60,0
80,0
100,0
0 500 1000 1500
time : min
MTGase Ajinomoto MTGase NP668
% pegylated 
Met-G-CSF 
Fig. 5 Kinetic profile functionality of NP668 versus Ajinomoto MTGase by comparing the enzymatic activities in covalent conjugation of 20 kDa
amine derivative of polyethylene glycol at glutamine 135 residue of Met-G-CSF
Table 4 Enzymatic activity of purified MTGase, comparison among
the two best performing expression systems and wild type
NP650C001 NP668C003 AJ021
LacZ1–8PNP1–20Met-MTGase LacZ1–8Met-MTGase Wild type
15,1 U/mg 24 U/mg 22 U/mg
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NP668/1 cell strain (Table 4). The lower activity obtained
for the LacZ1–8PNP1–20Met-MTGase could be attrib-
utable to the presence of the long PNP1–20 peptide
chain, therefore, despite the lower protein expression
yield obtained, the thermoinducible cell strain NP668/1
expression has been chosen as most performing expres-
sion system.
Comparison of the functionality of the LacZ1–8Met-
MTGase fusion protein (NP668/1) versus the Ajinomoto
“wild type” microbial transglutaminase showed a same
reaction kinetic profile for both products. In both cases
the reaction reached the plateau after four hours and the
reaction yields were comparable likewise the chromato-
graphic profiles (SE-HPLC) (Fig. 5).
Conclusions
Due to the implication of MTGase in many industrial
and pharmaceutical fields, the interest in finding the bet-
ter expression conditions of this enzyme is broadly wide-
spread [21].
In this work we have described a series of studies aimed
to determine the better strategy to express MTGase com-
paring constitutive versus thermoinducible expression sys-
tems rather than expressing the protein by fusion protein
or wild type. Moreover a comparison between two fusion
partner (LacZ1–8PNP1–20 and LacZ1–8) has been done. We
showed that the expression of a MTGase fusion protein is
advantageous in terms of fermentation yield and that the
use of the short LacZ1–8Met-MTGase fusion protein im-
proves the enzymatic activity of the product obtaining an
activity value comparable to that of the “wild type” trans-
glutamiase (Table 4).
Thereby, the importance to have a reliable protein activity
expression combined with a fast and robust method of
purification led to the choice of NP668/1 as reference strain
to produce Met-MTGase.
Competing interests
Bioker srl, is a biotech company located in the Scientific and Technological
Park of Sardinia (Italy) fully owned by Multimedica Holding. GS is a IRCCS
Multimedica employee; GT is CEO of Bioker srl while BS, DC, MB, SS and RS
are Bioker’s employees. GSJ is professor at University of Parma, Italy.
Authors’ contributions
BS was responsible of study development and manuscript writing. R.S. was
responsible of the research project. D.C. and G.T. were involved in experimental
design and manuscript writing. G.S. and G.S.J. were involved in scientific
advisory and manuscript drafting. SS was responsible for analytical studies
whereas MB for purification process. All authors read and approved the
final manuscript.
Acknowledgement
We acknowledge the Scientific and Technological Park of Sardinia that
financed the article-processing charge but had no role in study design,
preparation of the manuscript or decision to publish it.
Author details
1Bio-Ker S.r.l., Sardinia Scientific and Technological Park, Building 3, 09010
Pula, Cagliari, Italy. 2IRCCS MultiMedica, Milan, Italy. 3Department of
Biomedical, Biotechnological and Traslational Science (S.Bi.Bi.T.), University of
Parma, Via Volturno 39, 43121 Parma, Italy.
Received: 17 April 2015 Accepted: 2 September 2015
References
1. Yokoyama K, Nio N, Kikuchi Y. Properties and applications of microbial
transglutaminases. Appl Microbiol Biotechnol. 2004;64:447–54.
2. Bungay Peter J, Robin Owen A, Ian C, Griffin M. A role for transglutaminase
in glucose-stimulated insulin release from the pancreatic – cell. Biochem J.
1986;235:269–78.
3. Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac
and vascular diseases. Front Biosci. 2009;12:2530–45.
4. Griffin M, Casadio R, Bergamini CM. Transglutaminase. Nature’s biological
glue. Biochem J. 2002;368:377–96.
5. Fontana A, Spolaore B, Mero A, Veronese FM. Site-specific modification
and PEGylation of pharmaceutical proteins mediated by transglutaminase.
Adv Drug Deliv Rev. 2008;60:13–28.
6. Kieliszek M, Misiewicz A. Microbial transglutaminase and its application in
the food industry. A review. Folia Microbiol. 2014;59:241–50.
7. Kawajiri H, Ide H, Motoki M, Shimonishi Y. Priamry structure of microbial
transglutaminase from Streptoverticillium sp. Strain s-8112. J Biol Chem.
1993;268:11565–72.
8. Zotzel J, Keller P, Fuchsbauer HL. Transglutaminase from Streptomyces
mobaraensis is activated by an endogenous metalloprotease. Eur J Biochem.
2003;270:3214–22.
9. Zotzel J, Pasternack R, Pelzer C, Ziegert D, Mainusch M, Fuchsbauer HL.
Activated transglutaminase from Streptomyces mobaraensis is processed
by a tripeptidyl aminopeptidase in the final step. Eur J Biochem.
2003;270:4149–55.
10. Ando H, Adachi M, Umeda K, Matsuura A, Nonaka M, Uchio R, et al.
Purification and characteristics of a novel transglutaminase derived from
microorganisms. Agric Biol Chem. 1989;53:2613–7.
11. Washizu K, Ando K, Koikeda S, Hirose S, Matsuura A, Takagi H, et al. Molecular
cloning of the gene for microbial transglutaminase from Streptoverticillium
and its expression in Streptomyces lividans. Biosci Biotechnol Biochem.
1994;58:82–7.
12. Fu R, Chen J, Li Y. Heterologous leaky production of transglutaminase in
Lactococcus lactis significantly enhances the growth performance of the
host. Appl Environ Microbiol. 2005;71:8911–9.
13. Yokoyama K, Nakamura N, Saguaro K, Kubota K. Overproduction of microbial
transglutaminase in Escherichia coli, in vitro refolding, and characterization of
the refolded form. Biosci Biotechnol Biochem. 2000;64:1263–70.
14. Pozzuolo S, Breme U, Salis B, Taylor G, Tonon G, Orsini G. Efficient bacterial
expression of fusion proteins and their selective processing by a recombinant
Kex-1 protease. Protein Express Purif. 2008;59:334–41.
15. Sambrook J, Russell DW, editors. Molecular Cloning.A Laboratory Manual,
3rd ed. N.Y: Cold Spring Harbor Laboratory Press; 2001.
16. Elvin CM, Thompson PR, Argall ME, Hendry P, Stamford NP, Lilley PE.
Modified bacteriophage lambda promoter vectors for overproduction of
proteins in Escherichia coli. Gene. 1990;87:123–6.
17. Glascock CB, Weickert MJ. Using chromosomal lacIQ1 to control expression of
genes on high copy number plasmids in Escherichia coli. Gene. 1998;223:221–31.
18. Laemli UK. Cleavage of structural proteins during the assembly of the head
of bacteriophage T4. Nature. 1970;227(5259):680–5.15.
19. Folk JE, Cole PW. Transglutaminase: mechanistic features of the active site
as determined by kinetic and inhibitor studies. Biochim Biophys Acta.
1966;122:244–64.
20. Scaramuzza S, Tonon G, Olianas A, Messana I, Schrepfer R, Orsini G, Caliceti P.
A new site-specific monoPEGylated filgrastim derivative prepared by
enzymatic conjugation: Production and physiochemical characterization.
Journal of Controlled Release. 2012;164(3):355–63.
21. Liu S, Zhang D, Wang M, Cui W, Chen K, Du G, et al. The order of
expression is a key factor in the production of active transglutaminase in
Escherichia coli by coexpression with its pro-peptide. Microb Cell Fact.
2011;10:112.
Salis et al. BMC Biotechnology  (2015) 15:84 Page 11 of 11
